Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 181Lymphoma 97Lymphoma, Large B-Cell, Diffuse 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Sarcoma 69Hodgkin Disease 54Lymphoma, Non-Hodgkin 41Triple Negative Breast Neoplasms 37Burkitt Lymphoma 36Lymphoma, Mantle-Cell 32Leukemia 32Lymphoma, Follicular 30Multiple Myeloma 28Carcinoma, Hepatocellular 28Neoplasm Metastasis 23Ovarian Neoplasms 21Neoplasms 21Lymphoma, Large-Cell, Anaplastic 18Osteosarcoma 17Lymphoma, B-Cell 17Prostatic Neoplasms 16Neuroblastoma 15Lymphoma, T-Cell, Peripheral 15Urinary Bladder Neoplasms 14Recurrence 13Lymphoma, Large-Cell, Immunoblastic 13Inflammatory Breast Neoplasms 13Immunoblastic Lymphadenopathy 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Stomach Neoplasms 10

Interventions

fludarabine phosphate 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Cyclophosphamide 7Mycophenolic Acid 6Lenalidomide 6Dexamethasone 6Tacrolimus 5Bortezomib 4Sirolimus 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2Calcium Dobesilate 2Antilymphocyte Serum 2Allopurinol 2talquetamab 1sargramostim 1pomalidomide 1montanide ISA 51 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Plasma Cell × Doxorubicin × Clear all
NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡